vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $10.2M, roughly 1.8× Eightco Holdings Inc.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -2281.6%, a 2278.6% gap on every dollar of revenue. On growth, ROCKWELL MEDICAL, INC. posted the faster year-over-year revenue change (-25.6% vs -49.9%). ROCKWELL MEDICAL, INC. produced more free cash flow last quarter ($2.2M vs $-11.0M). Over the past eight quarters, Eightco Holdings Inc.'s revenue compounded faster (13.1% CAGR vs -10.1%).
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
ORBS vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $18.3M |
| Net Profit | $-232.5M | $-554.0K |
| Gross Margin | -13.0% | 21.1% |
| Operating Margin | -475.0% | -2.2% |
| Net Margin | -2281.6% | -3.0% |
| Revenue YoY | -49.9% | -25.6% |
| Net Profit YoY | -9183.3% | 26.7% |
| EPS (diluted) | $-2.34 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $18.3M | ||
| Q3 25 | $5.3M | $15.9M | ||
| Q2 25 | $7.6M | $16.1M | ||
| Q1 25 | $9.9M | $18.9M | ||
| Q4 24 | $20.3M | $24.7M | ||
| Q3 24 | $6.1M | $28.3M | ||
| Q2 24 | $5.3M | $25.8M | ||
| Q1 24 | $8.0M | $22.7M |
| Q4 25 | $-232.5M | $-554.0K | ||
| Q3 25 | $-25.8M | $-1.8M | ||
| Q2 25 | $-1.2M | $-1.5M | ||
| Q1 25 | $-2.5M | $-1.5M | ||
| Q4 24 | $-2.5M | $-756.0K | ||
| Q3 24 | $-3.2M | $1.7M | ||
| Q2 24 | $4.4M | $343.0K | ||
| Q1 24 | $1.9M | $-1.7M |
| Q4 25 | -13.0% | 21.1% | ||
| Q3 25 | -3.7% | 14.3% | ||
| Q2 25 | 16.4% | 15.6% | ||
| Q1 25 | 8.2% | 16.1% | ||
| Q4 24 | 8.2% | 14.7% | ||
| Q3 24 | 26.5% | 22.0% | ||
| Q2 24 | 25.1% | 17.6% | ||
| Q1 24 | 17.5% | 13.5% |
| Q4 25 | -475.0% | -2.2% | ||
| Q3 25 | -116.9% | -9.9% | ||
| Q2 25 | -15.9% | -8.4% | ||
| Q1 25 | -14.3% | -7.2% | ||
| Q4 24 | -11.9% | -2.1% | ||
| Q3 24 | -29.1% | 6.8% | ||
| Q2 24 | -16.4% | 2.0% | ||
| Q1 24 | -39.6% | -5.8% |
| Q4 25 | -2281.6% | -3.0% | ||
| Q3 25 | -487.6% | -11.0% | ||
| Q2 25 | -15.4% | -9.3% | ||
| Q1 25 | -25.7% | -8.0% | ||
| Q4 24 | -12.3% | -3.1% | ||
| Q3 24 | -52.5% | 5.9% | ||
| Q2 24 | 84.2% | 1.3% | ||
| Q1 24 | 24.4% | -7.6% |
| Q4 25 | $-2.34 | $-0.01 | ||
| Q3 25 | $-0.58 | $-0.05 | ||
| Q2 25 | $-0.38 | $-0.05 | ||
| Q1 25 | $-0.84 | $-0.04 | ||
| Q4 24 | $-1.44 | $-0.02 | ||
| Q3 24 | $-1.77 | $0.04 | ||
| Q2 24 | $2.15 | $0.01 | ||
| Q1 24 | $1.42 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.6M | $37.0M |
| Total Assets | $250.2M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $10.7M | ||
| Q3 25 | $23.7M | $13.6M | ||
| Q2 25 | $696.3K | $12.5M | ||
| Q1 25 | $434.4K | $11.4M | ||
| Q4 24 | $239.2K | $15.7M | ||
| Q3 24 | $2.4M | $12.3M | ||
| Q2 24 | $363.1K | $11.9M | ||
| Q1 24 | $808.8K | $6.6M |
| Q4 25 | $232.6M | $37.0M | ||
| Q3 25 | $339.2M | $37.0M | ||
| Q2 25 | $8.9M | $30.4M | ||
| Q1 25 | $9.7M | $31.5M | ||
| Q4 24 | $11.9M | $32.6M | ||
| Q3 24 | $13.0M | $29.1M | ||
| Q2 24 | $13.8M | $23.5M | ||
| Q1 24 | $3.9M | $20.6M |
| Q4 25 | $250.2M | $57.1M | ||
| Q3 25 | $355.5M | $57.5M | ||
| Q2 25 | $48.7M | $52.6M | ||
| Q1 25 | $47.6M | $54.0M | ||
| Q4 24 | $50.8M | $59.2M | ||
| Q3 24 | $49.2M | $57.1M | ||
| Q2 24 | $48.4M | $53.0M | ||
| Q1 24 | $50.2M | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $2.3M |
| Free Cash FlowOCF − Capex | $-11.0M | $2.2M |
| FCF MarginFCF / Revenue | -107.7% | 12.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $2.3M | ||
| Q3 25 | $-1.6M | $-1.3M | ||
| Q2 25 | $-659.2K | $1.8M | ||
| Q1 25 | $999.8K | $-3.5M | ||
| Q4 24 | $-6.6M | $865.0K | ||
| Q3 24 | $77.7K | $4.3M | ||
| Q2 24 | $-440.3K | $1.4M | ||
| Q1 24 | $-723.3K | $-2.4M |
| Q4 25 | $-11.0M | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | $-661.3K | $1.7M | ||
| Q1 25 | $999.7K | $-3.5M | ||
| Q4 24 | $-6.6M | $470.0K | ||
| Q3 24 | $73.0K | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | -107.7% | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | -8.7% | 10.5% | ||
| Q1 25 | 10.1% | -18.8% | ||
| Q4 24 | -32.7% | 1.9% | ||
| Q3 24 | 1.2% | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 1.6% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | -0.10× | 4.20× | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORBS
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
